Calcipotriene (Dovonex) Contraindications and Precautions
- hypercalcemia
- hypercalciuria
- hypervitaminosis D
- occlusive dressing
- ocular exposure
- accidental exposure
- breast-feeding
- children
- elderly
- nephrolithiasis
- pregnancy
- sunlight (UV) exposure
Calcipotriene (Dovonex) Contraindications and Precautions
Calcipotriene should not be used when hypercalcemia, hypervitaminosis D, or hypercalciuria are evident. Although systemic absorption of this agent is minimal, hypercalcemia, hypervitaminosis D, and/or hypercalciuria may occur (see Adverse Reactions). Hypercalcemia and/or hypercalciuria may increase renal calculi formation in patients with a history of nephrolithiasis. Topical application of more than 100 g/week should be avoided since hypercalcemia is more likely when this dose is exceeded. Do not cover with an occlusive dressing as this may enhance absorption of calcipotriene. Monitoring serum and urine calcium does not appear necessary during treatment at recommended dosages.
Calcipotriene should not be applied to the face; avoid ocular exposure. Accidental exposure to unaffected areas of skin or scalp margins may lead to skin irritation and should be avoided. Calcipotriene should be discontinued if irritation develops. In some instances skin irritation has resolved with continued use.
Age-related differences in treating psoriasis may result in increased sensitivity to calcipotriene. Although safety and efficacy of calcipotriene have not been established in children, children are at a greater risk of developing systemic adverse effects to topical medications because of a higher ratio of skin surface area to body mass. In the elderly, analysis of severity of dermatologic reactions occurring during clinical trials showed that subjects over 65 years had significantly more severe skin-related reactions than subjects under 65 years. Calcipotriene should be used cautiously in the elderly.
Calcipotriene is classified as FDA pregnancy risk category C. Adequate studies in pregnant women have not been conducted. Calcipotriene should be avoided during pregnancy or breast-feeding since adverse effects to the fetus or nursing infant may occur.
Calcipotriene should not be used in patients with a history of hypersensitivity reactions to the drug or any components used in the preparation of the commercial product.
Excessive exposure to natural or artificial sunlight (UV) exposure with topical application of calcipotriene may increase the risk of skin tumor formation and should be avoided.
[ Last revised: 5/7/2005 9:40:00 AM ]
Related entries
Syndicate
|
